Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rhei Pharmaceuticals and MethaPharma have announced that Rhei has licensed from MethaPharma the exclusive right to market and distribute Attental throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder or ADHD in children.
Subscribe to our email newsletter
Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated a significant improvement in the Conners’s Teaching Rating Scale-L (CTRS-L) of 59 items describing different aspects of child behavior, as well as in the Child Behavior Checklist (CBCL) – standard evaluation methods for ADHD.
Joos Horsten, executive chairman and CEO of Rhei, said: “Rhei will utilize its experience in pharmaceutical marketing and its network of contacts, particularly within the pediatric community, to bring this important natural remedy to the Asian market.”